Skip to main content
Fig. 2 | Respiratory Research

Fig. 2

From: Step up to triple therapy versus switch to dual bronchodilator therapy in patients with COPD on an inhaled corticosteroid/long-acting β2-agonist: post-hoc analyses of KRONOS

Fig. 2

Moderate/severe COPD exacerbation rate ratios: participants in the Exacerbations(No recent) populationa

aParticipants on ICS/LABA in the 30 days before screening and without exacerbation history in the previous 12 months.

BFF, budesonide/formoterol fumarate dihydrate (via MDI); BGF, budesonide/glycopyrronium/formoterol fumarate dihydrate; BUD/FORM, budesonide/formoterol fumarate dihydrate (via DPI); CI, confidence interval; COPD, chronic obstructive pulmonary disease; DPI, dry-powder inhaler; GFF, glycopyrronium/formoterol fumarate dihydrate; ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; MDI, metered-dose inhaler;

RR, rate ratio

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us